





ISO 22000 Certified Company

ISO 9001 : 2015 Certified Company

Date: 14-02-2025

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G Bandra Kurla Complex, Bandra East, Mumbai-400051 Scrip Code: MUKKA BSE Limited Listing Department Dalal Street, Mumbai-400001 Scrip Code: 544135

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on 14th February 2025.

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s), amendment(s) or reenactment(s) thereof for the time being in force), this is to inform you that the Board of Directors of the Company at their meeting held today i.e. 14th February 2025, have inter-alia approved the following business:

- 1. **Financial Results:** The unaudited financial results (standalone and consolidated) of the Company for the quarter and nine months period ended 31st December 2024. The same is enclosed. Further, the Limited Review Report received from the Statutory Auditors of the Company is also enclosed.
- 2. Change in Object Clause of the Company: The Board has approved alteration in object clause of Memorandum of Association (MOA) of the Company, in order to align the proposed business activities with the main objects of the MOA.
- **3.** To extend corporate guarantee to Ocean Proteins Private Limited: The Board has approved issuance of corporate guarantee of Rs. 15,00,00,000 (Rupees Fifteen Crores only) to Ocean Proteins Private Limited, associate company for securing its credit facilities.
- **4. Withdrawal of preferential issue of equity shares:** The Board has considered and approved the withdrawal of the Preferential Issue of 1,96,00,000 Equity Shares.

The detailed disclosures as required under SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 and such other circulars as applicable, in respect of point 2 and 3 are enclosed as Annexure I and II respectively.

The Meeting commenced at 5:30 p.m. and concluded at 6:00 p.m.

This is for your information and records.

Thank you,

For Mukka Proteins Limited

Mehaboobsab Mahmadgous Chalyal Company Secretary & Compliance Officer

Encl: as above.

E-mail: info@mukkaproteins.com - Website: www.mukkaproteins.com - CIN: L05004KA2010PLC055771



203, Center Point Building, 100, Dr. Babasaheb Ambedkar Road, Opp. Bharatmata Theater, Lalbaug, Parel, Mumbai - 400012.

Tel: - 022-42116800 Fax: 022 - 4022 0314 E-mail: info@shahtaparia.com

visit us at: www.shahtaparia.com

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors, **Mukka Proteins Limited**

- 1. We have reviewed the accompanying statement of unaudited Standalone Financial Results of Mukka Proteins Limited ('the Company'), for the quarter ended 31st December 2024 and year to date results for the period from 1st April 2024 to 31st December 2024, (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations") including relevant circulars issued by SEBI from time to time.
- 2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





203, Center Point Building, 100, Dr. Babasaheb Ambedkar Road, Opp. Bharatmata Theater, Lalbaug, Parel, Mumbai - 400012. Tel: - 022-42116800 Fax: 022 - 4022 0314

E-mail: info@shahtaparia.com visit us at: www.shahtaparia.com

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SHAH & TAPARIA

Chartered Accountants FRN: 109463W



Reg. No. 109483W

203, Centre Pord Billion

100, Bt. Raticellum (Nord.

Opp. Eberat Make Staerm.

Labous, Parol.

Member - 480012

Bharat Joshi

Partner

M. No.: 130863

UDIN: 25130863BM1QCY4431

Date: February 14, 2025

Place: Mumbai

Delhi Office: 52/74, Basement, Ramjas Road, Karol Baugh, New Delhi - 11005.

Tel.: 011-46051136 / 011-79632863 • E-mail : delhi@shahtaparia.com

MUKKA PROTEINS LIMITED (Earlier known as MUKKA SEA FOOD INDUSTRIES LIMITED)

CIN: L05004KA2010PLC055771

Statement of Unaudited Standalone Financial Results For The Quarter and Nine months ended December 31, 2024
(Rupees in million, except per share data and if otherwise stated)

Quarter Ended Nine Months ended Year ended December 31, September 30, December 31, December 31, March 31, 2024 Sr. December 31, 2023 Particulars 2024 2024 2024 2023 No. (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) Revenue from operations 2,799.90 12,308.20 Revenue from operations 1,217.41 4,683.09 5,443,64 10.068.96 Other operating income 69.49 43.46 153.27 170.81 308.82 377.23 Total Revenue from operations 2,869.39 1,260.87 12,685.43 4.836.37 5,614.45 10,377.78 Other income 62.30 29.21 62.57 122.15 135.40 168.74 3 Total income (1+2) 2,931.69 1,290.08 4,898.94 5,736.60 10,513.18 12,854.17 Expenses Cost of Material Consumed 3,178.33 1,177.12 5,096.03 5,888.82 9,680.81 12,492.02 Changes in inventories of finished goods, stock in trade and work in -1,020.78 -215.10 -775.80 -1,627.80 -835.86 -1,850.80 progress Employee benefits expenses 55.27 53.42 57.10 160.68 157.77 210.44 Finance costs 101.19 78.64 53.74 254.13 167.26 241.94 Depreciation and amortisation 14.34 41.63 13.80 15.93 45.04 56.20 expenses Other expenses 290.02 174.05 343.08 786.79 1,019.90 664.26 Total expenses 2,617.83 1,284.05 4,788.50 5,385.14 9,998.40 12,169.71 5 Profit before exceptional item and tax (3-4)313.86 6.02 110.44 351.46 514.78 684.46 **Exceptional** items 0.00 0.00 0.00 0.00 0.00 0.00 Profit before tax (5-6) 313.86 7 6.02 110.44 351.46 514.78 684.46 8 Share of Net Profit / (loss) of Associates 3.06 11.06 21.59 3.78 23.12 32.01 and Joint Ventures Total tax expenses 55.06 0.00 30.07 55.06 136.04 101.29 Current Tax -14.35 -0.96 11.28 6.37 -4.50 Deferred Tax -0.731.98 1.98 Earlier years 11.57 -3.70 0.19 7.87 285.94 404.39 627.56 21.74 90.49 10 Profit after tax (7+8-9) 251.02 Other Comprehensive Income/ (Expenses) (net of tax) Items that will not be reclassified to profit or loss -Remeasurements of the defined 1.59 -1.34-1.11 0.34 1.77 1.32 benefit plans 11 Other comprehensive income, net of 0.34 1.77 1.59 -1.34 -1.11 1.32 12 Total Comprehensive Income for the 22.07 92.26 287.52 403.05 626.44 252.34 Period (after tax) (10+11) Paid-up equity share capital (Face 300.00 220.00 300.00 300.00 300.00 220.00 Value of the share Rs. 1/- each) 0.00 0.00 0.00 0.00 0.00 3,351.73 Other equity 15 Earnings per share * (Face Value Rs. 1 /- per share) 1.84 2.78 0.84 0.07 0.41 0.96 (a) Basic 1.84 2.78 0.84 0.07 0.41 0.96 (b) Diluted

** Basic & Diluted EPS for all periods , except year ended March 31, 2024 , are not annualised. See accompanying notes to the financial results



MUKKA PROTEINS LIMITED (Earlier known as MUKKA SEA FOOD INDUSTRIES LIMITED) CIN: L05004KA2010PLC055771

Notes to the Statement of Unaudited Standalone Financial Results for the Quarter & Nine Months Ended December 31, 2024

- 1 The above statement of Unaudited standalone financial results for the Quarter & Nine months ended December 31, 2024 ('the Statement') of Mukka Proteins Limited ('the Company') are reviewed and recommended by the Audit Committee and taken on record by the Board of Directors at their meeting held on February 14, 2025. The Statutory auditors have carried out an review of the standalone financial results for the Quarter & Nine months ended December 31, 2024 and have issued an unmodified opinion on the same.
- The Company has completed its initial public offer ("IPO") of 8,00,00,000 fresh equity shares of face value of Rs. 1 each at an issue price of Rs. 28 per share (including share premium of Rs. 27 per share). On March 07, 2024 the equity shares of the company were listed on BSE Limited and National Stock Exchange (hereinafter referred to as "Stock Exchanges"). The total issue related expenses are Rs. 43.11 Crores. The Total utilization of IPO proceeds till December 31, 2024 is Rs. 185 808 Crores which is summarized below.

		East of the Principle of the Section 1		(Amount in Cro	ores)	
	Amount to be utilised as per Prospectus	Utilized as at beginning of	Illuring the	Utilized at the		
Funding working capital requirements of our Company	120.00	120.00	-	120.00		
Investment in our Associate, viz. Ento Proteins Private Limited, for funding its working capital requirements		10.00	-	10.00	_	
General corporate purposes	55.81	55.70	0.11	55.81	0.00	
Total	185,81	185.70	0.11	185.81	0.00	

As of 31st December, 2024, the Unutilized proceeds in the Bank total Rs. 0.066 crores of which represents the interest earned on fixed deposits has not been considered in the above calculations as the same is not part of the IPO proceeds actually received.

- 3 The unaudited Standalone Financial Results of the company are prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standard Rules), 2015 (as amended) and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended.
- 4 (i) The figures for the quarter ended December 31, 2024 are balancing figure between the unaudited figures for the Nine Months ended December 31, 2024 and published figures for Six months ended September 30, 2024.
 - (ii) The figures for the quarter ended December 31, 2023 are the balancing figures between the unaudited figures for the Nine Months ended December 31, 2023 and unaudited figures for the Six months ended September 30, 2023.
- 5 The Group operates in a single operating segment namely Fish & Fish Products. The Board of directors is the Chief Operating Decision Maker (the "CODM") of the group and makes operating decisions, assesses financial performance & allocates resources based upon discrete financial information. Since the Company operates in a single operating segment, separate segment reporting has not been made under Indian Accounting Standard ("Ind AS") 108 "Operating Segment". Further, the operation of the Group comprises of geographical segment as disclosed below Revenue disaggregation by geography is as follows:

						(Amount in Millions)	
		Quarter Ended			Nine Months ended		
Particulars		September 30, 2024	CHECK THE ART AND ART THE THE THE PARTY OF T		December 31, 2023	March 31, 2024	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
Within India	1,309.17	267.57	1,443.25	1,793.42	3,354.97	4,173.50	
Outside India	1,490.74	949.84	3,239.85	3,650.21	6,713.99	8,134.70	
Total	2,799.90	1,217.41	4,683.09	5,443.64	10,068.96	12,308.20	

The figures for comparative period have been regrouped/ reclassified, wherever necessary, to make them comparable.

The company faced scrutiny over the classification and tax rates for fish soluble paste. Some consignments were taxed at 5%, others at 18%, and several consignments were left untaxed. Consequently, the tax authorities demanded Rs. 98.27 Millions from the company for unpaid or underpaid GST. The company has filed an appeal online on 04.12.2024 and has paid the required deposit amounting to Rs. 9.83 Millions.

For and on behalf of Board of Directors of Mukka Proteins Limited

Date: February 14, 2025 Place: Mangalore



Managing Director and CEO DIN: 03020471



203, Center Point Building, 100, Dr. Babasaheb Ambedkar Road, Opp. Bharatmata Theater, Lalbaug, Parel, Mumbai - 400012.

Tel: - 022-42116800 Fax: 022 - 4022 0314 E-mail: info@shahtaparia.com

visit us at : www.shahtaparia.com

Independent Auditor's Review Report on Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors Mukka Proteins Limited

- 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Mukka Proteins Limited ("the Parent"), its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and Group's share of the net profit/loss after tax and total comprehensive income/loss of its associates and joint ventures, for the quarter and nine months ended December 31, 2024 and year to date from April 1, 2024 to December 31, 2024 ('the Statement') attached herein, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



203, Center Point Building, 100, Dr. Babasaheb Ambedkar Road, Opp. Bharatmata Theater, Lalbaug, Parel, Mumbai - 400012.

Tel: - 022-42116800 Fax: 022 - 4022 0314 E-mail: info@shahtaparia.com visit us at: www.shahtaparia.com

4. The Statement includes the results of the following entities:

Name of the Entity	Relationship
Mukka Proteins Limited	Parent Company
Haris Marine Private Limited	Subsidiary Company (Domestic)
Alantic Marine Private Limited	Subsidiary Company (Domestic)
Ocean Aquatic Proteins LLC	Subsidiary Company (Foreign)
Ento Proteins Private Limited	Subsidiary Company (Domestic)
Ocean Proteins Private Limited	Associates
Ullal Fish Meal and Oil Company	Joint Venture
Progress Frozen and Fish Sterilization	Joint Venture
Pacific Marine Products	Joint Venture
Mangalore Fishmeal and Oil Company	Joint Venture - Indirect

- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. We did not review the interim financial information/ financial results of four subsidiaries included in the Statement, whose interim financial information/ financial results reflect total revenues of Rs. 504.78 million and Rs. 1331.19 million for the quarter and nine months ended December 31, 2024 respectively, total net profit after tax of Rs. 23.91 million and Rs. 68.96 million for the quarter and nine months ended December 31, 2024 respectively and total comprehensive income/ (loss) of Rs. 18.88 million and Rs. 63.01 million for the quarter and nine months ended December 31, 2024 respectively as considered in the Statement which have been reviewed by other auditors, whose reports has been furnished to us by the Company's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Further, we did not review the interim financial information/ financial results of One Associate & Four Joint Ventures included in the Statement, whose interim financial information/ financial results reflect share of profit amounting to Rs. 5.22 million and Rs. 11.58 million for the quarter and nine months ended December 31, 2024 respectively, total comprehensive profit amounting to Rs. 5.22 million and Rs. 11.58 million for the quarter and nine months ended December 31, 2024 respectively as considered in the statement which have been reviewed by other auditors, whose reports have been furnished to us by the Company's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these



203, Center Point Building, 100, Dr. Babasaheb Ambedkar Road, Opp. Bharatmata Theater, Lalbaug, Parel, Mumbai - 400012. Tel :- 022-42116800 Fax : 022 - 4022 0314

E-mail: info@shahtaparia.com

visit us at : www.shahtaparia.com

subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

For SHAH & TAPARIA

Chartered Accountants

FRN: 109463W

X

Bharat Joshi

Partner

M. No.: 130863

UDIN: 25130863BM1QCZ8002

Date: February 14, 2025

Place: Mumbai

Delhi Office: 52/74, Basement, Ramjas Road, Karol Baugh, New Delhi - 11005.

Tel.: 011-46051136 / 011-79632863 • E-mail : delhi@shahtaparia.com

MUKKA PROTEINS LIMITED (Earlier known as MUKKA SEA FOOD INDUSTRIES LIMITED) CIN: L05004KA2010PLC055771

Statement of Unaudited Consolidated Financial Results For the Quarter & Nine Months Ended December 31, 2024

(Rupees in million, except per share data and if otherwise stated) Quarter Ended Nine Months Ended Year ended December 31, 2024 | September 30, 2024 | December 31, 2023 | December 31, 2024 | December 31, 2023 March 31, 2024 Sr. No Particulars (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1 Revenue from Operations 13,421.06 Revenue from operations 2,962.04 1,448.48 5,016.58 6,077.64 10,922.50 Other operating income 69.49 43.46 153.27 170.8 308.82 377.23 Total Revenue from operations 3,031.52 1,491.94 5,169.85 6,248.45 11,231.32 13,798,29 163.15 2 Other income 57.98 31.40 61.82 117.91 130.39 Total income 3,089.51 1,523.34 5,231.67 6,366.35 11,361.72 13,961.43 Expenses 10,376.73 13,268.75 Cost of Material Consumed 1,292.28 6,615.0 3.418.61 Changes in inventories of finished goods, stock in trade and work in progress -1,209.74 -169.73 -958.39 -1,987.5 -940.52 -1,913.57 Employee benefits expenses 84.34 83.06 79.76 237.32 216.63 293.31 250.96 Finance costs 109.07 87.24 61.52 277.60 184.69 89.99 123.38 37.56 31.81 107.30 Depreciation and amortisation expenses 37.96 1,095.10 324.78 190.67 726.5 845.70 Other expenses 371.15 2,765.03 1,521.09 5,074.40 5,976.28 10,773.23 13,117.94 Total expenses 5 Profit before exceptional item, Share of Net Profit / (loss) of Associates and Joint 843.50 2.25 157.27 390.0 588.49 324.48 Ventures and tax (3-4) 0.00 0.00 0.00 0.00 Exceptional items 0.00 0.00 6 16.50 31.06 Share of Net Profit / (loss) of Associates and Joint Ventures 5.22 8.26 11.58 10.51 174.67 401.65 605.00 874.56 Profit before tax (5-6+7) 329.70 Total tax expenses 156.08 143.23 Current Tax 55.95 11.88 42.55 62.13 Deferred Tax -4.60 -14.51 -1.27 -1.16 11.21 6.45 -14.93 0.22 -7.90 2.00 2.78 Earlier years 7.03 451.52 743.05 Profit for the period 267.99 14.71 120.70 340.97 11 Other Comprehensive Income Items that will not be reclassified subsequently to profit or loss Remeasurement of the net defined benefit plans 1.32 0.34 1.77 1.59 -1.34 -1.11 Items that will be reclassified subsequently to profit or loss -1.50 -2.12 0.87 -0.43 -4.08 -2.67 Exchange differences on translation of foreign operations -1.35 1.20 1.34 -2.50 -2.83 -3.23 12 Total other comprehensive income 448.68 739.82 338.48 13 Total comprehensive income for the period 266.65 15.92 122.04 Profit for the year attributable to: 700.52 Shareholders of the Company 262.61 20.80 104.74 328.73 428.83 42.53 22.69 Non-controlling interests 5.38 -6.09 15.96 12.24 Other comprehensive income for the year attributable to: -0.36 0.88 1.5 -0 99 -2.28 -2.45 Shareholders of the Company -0.78 Non-controlling interests -0.99 0.32 -0.16 -1.51 -0.55 220.00 300.00 220.00 300.00 300.00 300.00 Paid-up equity share capital (Face Value of the share Re. 1/- each) * 12 3,660.90 0.00 0.00 0.00 0.00 0.00 13 Other equity 14 Earnings per share * (Face Value Rs. 1 /- per share) 0.07 0.48 1.10 1.95 3.10 (a) Basic 3.10 0.88 0.07 0.48 1.10 1.95 (b) Diluted

** Basic & Diluted EPS for all periods , except year ended March 31, 2024 , are not annualised. See accompanying notes to the financial results



MUKKA PROTEINS LIMITED as MUKKA SEA FOOD INDUSTRIES LIMITED) CIN: L05004KA2010PLC055771

Notes to the Statement of Unaudited Consolidated Financial Results for the Quarter & Nine Months Ended December 31, 2024

- 1 The above statement of unaudited consolidated financial results for the Quarter & Nine months ended December 31, 2024 ('the Statement') of Mukka Proteins Limited ('the Company') are reviewed and recommended by the Audit Committee and taken on record by the Board of Directors at their meeting held on February 14, 2025. The Statutory auditors have carried out an review of the consolidated financial results for the Quarter & Nine months ended December 31, 2024 and have issued an unmodified opinion on the same.
- The Company has completed its initial public offer ("IPO") of 8,00,00,000 fresh equity shares of face value of Rs. 1 each at an issue price of Rs. 28 per share (including share premium of Rs. 27 per share). On March 07, 2024 the equity shares of the company were listed on BSE Limited and National Stock Exchange (hereing the stock Exchanges"). The total issue related expenses are Rs. 43.11 Crores. The Total utilization of IPO proceeds till December 31, 2024 is Rs. 185.808 Crores which is summarized below:

Purpose	Amount to be utilised as per Prospectus	Amount Utilized as at beginning of the Ouarter	Amount Utilized During the Ouarter	Total Amount Utilized at the end of Quarter	(Amount in Crores) Unutilized as on December 31, 2024
Funding working capital requirements of our Company	120.00	120.00		120.00	-
Investment in our Associate, viz. Ento Proteins Private Limited, for funding its working capital requirements		10.00		10.00	-
General corporate purposes	55.81	55.70	0.11	55.81	0.00
Total	185.81	185.70	0.11	185.81	0.00

As of 31st December , 2024, the Unutilized proceeds in the Bank total Rs. 0.066 crores of which represents the interest earned on fixed deposits has not been considered in the above calculations as the same is not part of the IPO proceeds actually received.

- The Unaudited Consolidated Financial Results of the company are prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standard Rules), 2015 (as amended) and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended.
- 4 (i) The figures for the quarter ended December 31, 2024 are balancing figure between the unaudited figures for the Nine Months ended December 31, 2024 and published figures for Six months ended September 30, 2024.
 - (ii) The figures for the quarter ended December 31, 2023 are the balancing figures between the unaudited figures for the Nine Months ended December 31, 2023 and unaudited figures for the Six months ended September 30, 2023.
- 5 The Group operates in a single operating segment namely Fish & Fish Products. The Board of directors is the Chief Operating Decision Maker (the "CODM") of the group and makes operating decisions, assesses financial performance & allocates resources based upon discrete financial information. Since the Company operates in a single operating segment, separate segment reporting has not been made under Indian Accounting Standard ("Ind AS") 108 - "Operating Segment". Further, the operation of the Group comprises of geographical segment

Revenue disaggregation by geography is as follows:-

(Amount in Millione)

	Quarter Ended			Nine Month	Year Ended	
Particulars	December 31, 2024	September 30, 2024	December 31, 2023	December 31, 2024	December 31, 2023	March 31, 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Within India	1,774.38	274.38	1,454.91	2,273.50	2,507.47	3,233.21
Outside India	1,187.66	1,174.09	3,561.66	3,804.13	8,415.03	10,187.85
Total	2,962.04	1,448.48	5,016.58	6,077.64	10,922.50	13,421.06

6 The Consolidated Financial Results for the Quarter & Nine Months Ended December 31, 2024 are summarized below and detailed financial report is also available on the Stock Exchange website, www.nseindia.com, www. bseindia.com and Parent Company's website www.mukkaproteins.com

PARTICIPATE DE L'ARTE DE L	CARCAL MINISTRANCE AND ADDRESS OF THE PERSON		The second secon	Employed Company of the Company of t		(Fancant in Francois)
	Quarter Ended			Nine Mont	Year ended	
Particulars	December 31, 2024	September 30, 2024	December 31, 2023	December 31, 2024	December 31, 2023	March 31, 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Revenue from operations	2,962.04	1,448.48	5,016.58	6,077.64	10,922.50	13,421.06
Profit brfore tax	329.70	10.51	174.67	401.65	605.00	874.56
Profit after tax	267.99	14.71	120.70	340.97	451.52	743.05
Total Comprehensive Income	266.65	15.92	122.04	338.48	448.68	739.82

The company faced scrutiny over the classification and tax rates for fish soluble paste. Some consignments were taxed at 5%, others at 18%, and several consignments were left untaxed. Consequently, the tax authorities demanded Rs. 98.27 Millions from the company for unpaid or underpaid GST. The company has filed an appeal online on 04.12.2024 and has paid the required deposit amounting to Rs. 9.83 Millions.

The figures for comparative period have been regrouped/ reclassified, wherever necessary, to make them comparable.

The Company has completed the disinvestment of its entire stake in MSFI (Bangladesh) Limited on December 17, 2024 for USD 14,038.44 (₹11,82,738.57). Consequently, MSFI (Bangladesh) Limited has ceased to be an Associate Company.

MANGALURU

For and on behalf of Board of Directors of Mukka Proteins Limited

> Kalandan Mohammed Haris Managing Director and CEO DIN: 03020471

Date: February 14, 2025 Place: Mangalore

Annexure I

Summary of amendments to the MOA of the Company

Sl. No.	Amendments/Changes
1	The following sub clause (3), (4) and (5) to be appended after sub clause (2) of clause 3 (A) of the Memorandum of Association of Company:
	3. To carry on the business as manufacturers, importers, exporters, buyers, sellers, dealers, wholesalers, retailers and distributing agents and dealers in developing ingredients from insects, bugs for human consumption, animal feeds and consumptions, medical preparations, and all types of various food grains for animal consumption including the ones which can be used for aqua feeds and to offer a range of products to optimise the feed solutions and to carry on the business of research and engineering, design, to improve the production and quality, controllability, efficiency and overall competitiveness and improvement of production lines relating to the said objects.
	4. Dealing in waste management, Leachate water treatment related activities, sourcing of all sorts of waste including plastic, Metal, organic, Food and other biological waste etc. by charging user fee from clients and convert them into value added products, thus solving the waste problem and generate income by selling the output, to provide specialized waste management services, Offering environmentally friendly solutions, that can help set our business apart from competitors and collaboration with other businesses in the industry which lead to new opportunities and growth.
	5. To carry on the business of manufacturing, processing, formulating, importing, exporting, trading, distributing, and dealing in humic acid, fulvic acid, organic and inorganic compost, fertilizers, manure, pesticides and other organic soil conditioners, bio-stimulants, fertilizers, agrochemicals, and allied products for agricultural, horticultural, and industrial applications and to establish, acquire, own, operate, and maintain manufacturing units, processing plants, warehouses, and distribution networks for the production and supply of humic acid and related products.

Annexure II

S.	Particulars	Details
No.		
1.	Name of party for which such guarantees	Ocean Proteins Private Limited, Associate
	or indemnity or surety was given	Company
2.	Whether the promoter/ promoter group/	The Promoters are interested to the extent of their
	group companies have any interest in this	directorship in Ocean Proteins Private Limited.
	transaction? If yes, nature of interest and	
	details thereof and whether the same is	The corporate guarantee will be provided by the
	done at "arms length"	Company on an arm's length basis.
3.	Brief details of such guarantee or	Ocean Proteins Private Limited is availing a
	indemnity or becoming a surety viz. brief	General Purpose Corporate Loan facility of up to
	details of agreement entered (if any)	Rs. 15,00,00,000/- (Rupees Fifteen Crores Only)
	including significant terms and conditions,	from Bajaj Finance Limited.
	including amount of guarantee	
		The Company is issuing corporate guarantee in
		favour of Bajaj Finance Limited to secure the
		said General Purpose Corporate Loan facility
		being availed by Ocean Proteins Private Limited.
		Corporate Guarantee Agreement is yet to be
		executed in this regard.
4.	Impact of such guarantees or indemnity or	The corporate guarantee provided by the
	surety on listed entity	Company will be a contingent liability for the
	Salety on holed energy	Company to the extent of facility to be availed
		by Ocean Proteins Private Limited.
		by Occan Florenis Flivate Linnicu.